Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development

Shogo Takahashi, Naoki Tanaka, Tatsuki Fukami, Cen Xie, Tomoki Yagai, Donghwan Kim, Thomas J. Velenosi, Tingting Yan, Kristopher W. Krausz, Moshe Levi, Frank J. Gonzalez – 1 October 2018 – Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths worldwide, and an association between altered bile acid (BA) metabolism, down‐regulation of farnesoid X receptor (FXR), which is a master regulator of BA metabolism, and hepatocarcinogenesis has been documented.

Evaluating Women’s Preferences for Hepatitis C Treatment During Pregnancy

Tatyana Kushner, Jennifer Cohen, Phyllis C. Tien, Norah A. Terrault – 1 October 2018 – There is a rising prevalence of hepatitis C (HCV) among women of child‐bearing age nationally, which prompted a recommendation by national guidelines to screen all women for HCV during pregnancy. Women with HCV during pregnancy are at risk of perinatal transmission of HCV. Directly acting antiviral (DAA) therapy during pregnancy can potentially reduce the risk of perinatal transmission as well as cure women while they are engaged in antenatal care.

Perinatal Nutritional Reprogramming of the Epigenome Promotes Subsequent Development of Nonalcoholic Steatohepatitis

Luz Helena Gutierrez Sanchez, Kyoko Tomita, Qianqian Guo, Kunimaro Furuta, Husam Alhuwaish, Petra Hirsova, Saurabh Baheti, Bonnie Alver, Ryan Hlady, Keith D. Robertson, Samar H. Ibrahim – 1 October 2018 – With the epidemic of obesity, nonalcoholic fatty liver disease (NAFLD) has become the most common pediatric liver disease. The influence of a perinatal obesity‐inducing diet (OID) on the development and progression of NAFLD in offspring is important but incompletely studied.

Living Donor Liver Transplantation Using Selected Grafts With 2 Bile Ducts Compared With 1 Bile Duct Does Not Impact Patient Outcome

Dagmar Kollmann, Nicolas Goldaracena, Gonzalo Sapisochin, Ivan Linares, Nazia Selzner, Bettina E. Hansen, Mamatha Bhat, Mark S. Cattral, Paul D. Greig, Les Lilly, Ian D. McGilvray, Anand Ghanekar, David R. Grant, Markus Selzner – 28 September 2018 – The outcome after living donor liver transplantation (LDLT) using grafts with multiple bile ducts (BDs) remains unclear. We analyzed 510 patients who received an adult‐to‐adult right lobe LDLT between 2000 and 2015 and compared outcome parameters of those receiving grafts with 2 BDs (n = 169) with patients receiving grafts with 1 BD (n = 320).

Lymphoid Enhancer Factor 1 Contributes to Hepatocellular Carcinoma Progression Through Transcriptional Regulation of Epithelial‐Mesenchymal Transition Regulators and Stemness Genes

Chih‐Li Chen, Yu‐Shuen Tsai, Yen‐Hua Huang, Yuh‐Jin Liang, Ya‐Yun Sun, Chien‐Wei Su, Gar‐Yang Chau, Yi‐Chen Yeh, Yung‐Sheng Chang, Jui‐Ting Hu, Jaw‐Ching Wu – 28 September 2018 – Lymphoid enhancer factor 1 (LEF1) activity is associated with progression of several types of cancers. The role of LEF1 in progression of hepatocellular carcinoma (HCC) remains poorly known.

Prohibitin 1 Acts As a Negative Regulator of Wingless/Integrated‐Beta‐Catenin Signaling in Murine Liver and Human Liver Cancer Cells

Nirmala Mavila, Yuanyuan Tang, Joshua Berlind, Komal Ramani, Jiaohong Wang, José M. Mato, Shelly C. Lu – 27 September 2018 – Prohibitin1 (PHB1) is a mitochondrial chaperone with diverse functions that include cell proliferation, apoptosis, and mitochondrial homoeostasis. Liver‐specific Phb1 knockout (KO) mice develop spontaneous injury and hepatocellular carcinoma (HCC). Our previous work demonstrated that PHB1 negatively regulates the H19‐insulin‐like growth factor 2 (IGF2)‐H19‐IGF2 axis signaling pathway and E‐box activity in hepatocytes and HCC cells.

Subscribe to